Last reviewed · How we verify
HRS-1780 Tablets
HRS-1780 is an investigational small molecule with unknown mechanism of action in Phase 3 development.
At a glance
| Generic name | HRS-1780 Tablets |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding the specific molecular mechanism of HRS-1780. As a Phase 3 candidate from Shandong Suncadia Medicine Co., Ltd., the drug is in late-stage clinical development, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease (PHASE3)
- A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism (PHASE2)
- Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease (PHASE2)
- Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human (PHASE1)
- Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects (PHASE1)
- Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |